利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

55 条记录 (耗时 0.022 秒)

    Inhibition of pathogenic agents including α6β1 integrin receptor or α6β4 integrin receptor at a surface
    14.
    发明授权
    Inhibition of pathogenic agents including α6β1 integrin receptor or α6β4 integrin receptor at a surface 失效
    包括α6和bgr1整联蛋白受体或α6和bgr4整合素受体在表面的致病因子的抑制

    公开(公告)号：US07838000B2

    公开(公告)日：2010-11-23

    申请号：US11440746

    申请日：2006-05-25

    申请人： Thomas R. Scott ,  Heather P. Borick ,  Ginger A. Swire-Clark ,  William R. Marcotte, Jr. ,  Ashby B. Bodine

    发明人： Thomas R. Scott ,  Heather P. Borick ,  Ginger A. Swire-Clark ,  William R. Marcotte, Jr. ,  Ashby B. Bodine

    IPC分类号： A61K39/00 ,  A61K38/00

    CPC分类号： C07K14/78 ,  A61K38/00 ,  A61K38/1777 ,  C07K2319/00

    摘要： Disclosed are treatment agents and methods of treatment utilizing the agents directed toward diseases in which the disease causing pathogen includes α6β1 integrin receptors and/or α6β4 integrin receptors on the surface of the pathogen. In one embodiment, the disease can be breast cancer. The therapeutic agents disclosed include a polypeptide comprising at least a portion of the G domain of the laminin-5 α3 chain that has been shown to bind α6β1 integrin receptors and α6β4 integrin receptors. In one embodiment, the therapeutic agents can be fused or chimeric materials in which the laminin-5 α3 chain polypeptide has been chemically bound to another material that can be useful in the destruction or neutralization of the pathogen.

    摘要翻译： 公开了治疗剂和治疗方法，其使用针对致病病原体的疾病的试剂在病原体表面包含α6和bgr1整联蛋白受体和/或α6＆bgr4整联蛋白受体。 在一个实施方案中，该疾病可以是乳腺癌。 所公开的治疗剂包括包含已经显示结合α6和bgr1整联蛋白受体和α6和bgr4整联蛋白受体的层粘连蛋白-5α3链的至少一部分G结构域的多肽。 在一个实施方案中，治疗剂可以是其中层粘连蛋白-5α3链多肽化学结合到另一种可用于破坏或中和病原体的材料的融合或嵌合物质。

    Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin αvβ3 and medical use thereof
    16.
    发明授权
    Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin αvβ3 and medical use thereof 有权
    用于鉴定lap（潜伏相关肽）和整合蛋白alphavbeta3之间的相互作用的调节剂的方法及其医疗用途

    公开(公告)号：US07037666B2

    公开(公告)日：2006-05-02

    申请号：US10276947

    申请日：2001-05-25

    申请人： Simon Barry ,  Carmel Horgan ,  Steven Ludbrook ,  David Miller

    发明人： Simon Barry ,  Carmel Horgan ,  Steven Ludbrook ,  David Miller

    IPC分类号： G01N33/53

    CPC分类号： A61K38/1777 ,  A61K38/1841 ,  G01N2333/70557 ,  G01N2500/00

    摘要： A method for the identification of a modulator of the interaction between latency asssociated peptide (LAP) of transforming growth factor β1 (TGF-β1) and the integrin avb3, which method comprises: (a) providing, as a first component, LAP-β1 or a functional variant thereof (b) providing, as a second component, integrin avb3 or a functional variant thereof (c) contacting the two components with a test product under conditions that, in the absence of the test product, would permit the two components to interact; and (d) determining whether the test product is capable of modulating the interaction between the first and second components, thereby to determine whether the test product is a modulator of the interaction between LAP-β1 and integrin avb3.

    摘要翻译： 鉴定转化生长因子β1（TGF-β1）的潜伏相关肽（LAP）与整联蛋白α3β3之间相互作用的调节剂的方法， 该方法包括：（a）作为第一组分提供LAP-β1或其功能变体（b）提供作为第二组分的整联蛋白α3/ >或其功能变体（c）在不存在测试产物的情况下允许两种组分相互作用的条件下将两种组分与测试产物接触; 和（d）确定测试产品是否能够调节第一和第二组分之间的相互作用，从而确定测试产品是否是LAP-β1和整联蛋白之间相互作用的调节剂， b 3 3。

    Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients
    17.
    发明申请
    Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients 失效
    预防和治疗癌症患者的肿瘤生长，转移和血栓栓塞并发症

    公开(公告)号：US20040214751A1

    公开(公告)日：2004-10-28

    申请号：US10125882

    申请日：2002-04-22

    发明人： Mawaheb M. El-Naggar ,  Shaker A. Mousa

    IPC分类号： A61K038/14

    CPC分类号： A61K45/06 ,  A61K9/0019 ,  A61K38/1777 ,  A61K47/36 ,  A61K2300/00

    摘要： This invention provides for the prevention and treatment of tumor growth, metastasis, and cancer-mediated thrombosis through the administration, in combination, of a short or long acting GPIIb/IIIa antagonist (A) and anticoagulant (B) that might include the following: UFH or low molecular weight heparin, (LMWH), ultra LMWH, pentasaccharide or direct anti-Xa or direct anti-IX/IXa, direct anti-IIa (thrombin) or tissue factor pathway inhibitor (TFPI) by any means that produces contact of the agents with their site of action wherein at least one of the components of each of these combinations is given in reduced amount. This combined formulation could be used as a stand-alone regimen or in conjunction with other therapies (chemotherapy, radiotherapy, angiogenesis inhibitors, . . . ), and pre- & post-tumor surgery in the prevention and treatment of cancer associated metastasis, angiogenesis, tumor growth, and thrombosis.

    摘要翻译： 本发明通过组合施用可能包括以下的短效应或长效GPIIb / IIIa拮抗剂（A）和抗凝血剂（B）来预防和治疗肿瘤生长，转移和癌症介导的血栓形成： UFH或低分子量肝素（LMWH），超LMWH，五糖或直接抗Xa或直接抗IX / IXa，直接抗IIa（凝血酶）或组织因子途径抑制剂（TFPI）通过任何方式产生接触 具有其作用位点的试剂，其中以减少的量给予这些组合中的每一种的至少一种组分。 该组合制剂可用作独立方案或与其他疗法（化学疗法，放射治疗，血管生成抑制剂，...）和肿瘤前和手术后预防和治疗癌症相关转移，血管生成 ，肿瘤生长和血栓形成。